---
title: "Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma"
description: "The goal of this study is to evaluate the efficacy and safety of the novel form of trans-scleral cyclophotocoagulation using micropulse diode laser and tra"
url: "https://www.clareohealth.com/clinical-trials/NCT03187418"
---

The goal of this study is to evaluate the efficacy and safety of the novel form of trans-scleral cyclophotocoagulation using micropulse diode laser and trans-pars plana treatment (Micropulse TSCPC, mTSCPC MP3, IRIDEX CYCLO G6™ Glaucoma Laser System, CA, USA) in adults for the treatment of uncontrolled glaucoma.

## Key Facts

**ID:** NCT03187418
**Status:** COMPLETED
**Phase:** NA
**Type:** INTERVENTIONAL
**Enrollment:** 52
**Sponsor:** Centre hospitalier de l'Université de Montréal (CHUM)

## About This Study

This clinical trial is testing a new laser treatment called MicroPulse trans-scleral cyclophotocoagulation (mTSCPC) for adults with uncontrolled glaucoma. The goal is to see how effective and safe this treatment is compared to traditional methods.

## Detailed Description

Cyclophotocoagulation (CPC) is a type of cycloablation using laser to treat glaucoma. It involves ciliary body destruction by targeting the ciliary epithelium and stroma, resulting in a reduction in aqueous secretion and hence intraocular pressure. This strategy is effective for all forms of glaucoma. Traditional trans-scleral cyclophotocoagulation (TSCPC) achieve its cyclodestructive action by using continuous diode laser to target the melanin in the pigmented ciliary body epithelium. However, the continuous mode has been shown to cause significant collateral tissue damage to adjacent non-pigmented structures including the ciliary stroma and ciliary muscle. Traditional TSCPC may therefore be associated with serious complications including uveitis, visual deterioration, chronic hypotony, and others. More recently, a micropulse delivery mode of diode laser (Micropulse TSCPC, mTSCPC) has been used to treat glaucoma by ablating the ciliary processes and reduce aqueous humor production with more selective targeting and less collateral damage. In contrast to conventional laser delivery where a continuous flow of high intensity energy is delivered, micropulse laser application delivers a series of repetitive short pulses of energy with rest periods in between pulses. Only a few studies have described the outcomes of this novel glaucoma therapy, showing mTSCPC to have comparable efficacy with fewer side effects when compared with traditional continuous wave mode diode laser delivery.This improved side effect profile has the potential to make mTSCPC an earlier therapeutic option instead of reserving it exclusively for end-stage refractory eyes.

## Conditions

- Glaucoma
- Glaucoma, Open-Angle
- Glaucoma, Neovascular
- Glaucoma and Ocular Hypertension
- Glaucoma Eye
- Glaucoma, Uncompensated
- Glaucoma Secondary

## Interventions

**DEVICE: MicroPulse® P3 Glaucoma Device (MP3)**
Laser settings will be programmed as follows: power-2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse "on" time-0.5ms; micropulse "off" time-1.1ms; and duty cycle (proportion of each cycle during which the laser is on)-31.33 %. The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus). The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s).

## Eligibility

Inclusion Criteria: * Patients of either sex and any race aged 18 years old and above. * Followed by a glaucoma subspecialist at University of Montreal Hospital Center.

## Who Can Participate

**Minimum age:** 18

**Sex:** ALL

**Accepts healthy volunteers:** Yes

## Study Locations

- Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada

## Contact Information

## Important Dates

**Study start:** June 19, 2017

**Completion date:** February 15, 2020

**Last updated:** October 8, 2021

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have uncontrolled glaucoma that hasn't responded well to medications.
- Your eye pressure is higher than the target range despite treatment.
- You are considered a poor candidate for more invasive surgeries for glaucoma.

### Questions to Ask

- What are the expected benefits of the MicroPulse treatment compared to my current options?
- What side effects should I be aware of with this new treatment?
- How will my progress be monitored during the trial?
- What happens if I experience complications during the treatment?
- How long will the treatment take, and how often will I need to visit the clinic?
- Am I a good candidate for this trial based on my current glaucoma condition?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03187418)
